Loading...
Please wait, while we are loading the content...
Similar Documents
18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Binderup, Tina Knigge, Ulrich P. Loft, Annika Federspiel, Birgitte Hartnack Kjaer, Andreas |
| Copyright Year | 2010 |
| Abstract | PURPOSE (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. EXPERIMENTAL DESIGN Ninety-eight prospectively enrolled patients with NE tumors underwent FDG-PET imaging. FDG uptake was quantified by maximal standardized uptake value (SUVmax). The prognostic value of FDG uptake, proliferation index, chromogranin A, and liver metastases were assessed. RESULTS During the 1-year follow-up, 14 patients died. The diagnostic sensitivity of FDG-PET was 58% (n = 57) and a positive FDG-PET result was associated with a significantly higher risk of death with a hazard ratio (HR) of 10.3 [95% confidence interval (CI), 1.3-78.9]. Thirteen of the 57 (23%) FDG-PET-positive patients died compared with 1 of 41 (2%) FDG-PET-negative patients. By univariate analysis, a SUVmax of >9 and a high Ki67 index were significant predictors of overall survival with a HR of 8.8 (95% CI, 2.7-28.7) and a HR of 2.6 (95% CI, 1.3-5.1), respectively. In a multivariate analysis including a SUVmax of >3, Ki67, and chromogranin A, SUVmax of >3 was the only predictor of progression-free survival (HR, 8.4; P < 0.001). CONCLUSIONS This study shows a strong prognostic value of FDG-PET for NE tumors, which exceeds the prognostic value of traditional markers such as Ki67, chromogranin A, and liver metastases. FDG-PET may obtain an important role for NE tumors. |
| Starting Page | 1342 |
| Ending Page | 1343 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/16/3/978.full.pdf |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/early/2010/01/25/1078-0432.CCR-09-1759.full.pdf |
| PubMed reference number | 20103666v1 |
| Alternate Webpage(s) | https://doi.org/10.1158/1078-0432.CCR-09-1759 |
| DOI | 10.1158/1078-0432.ccr-09-1759 |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Volume Number | 16 |
| Issue Number | 3 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Cessation of life Chromogranin A Chromogranins Confidence Intervals Diagnostic Techniques, Urological FDG-Positron Emission Tomography Fluorodeoxyglucose F18 Hazard Ratio Liver diseases Neuroendocrine Tumors Neurosecretory Systems Overall Survival PET/CT scan Patients Pet Therapy Pituitary Neoplasms Positron-Emission Tomography Positrons Progression-Free Survival Standardized Uptake Value Maximum X-Ray Computed Tomography |
| Content Type | Text |
| Resource Type | Article |
